Dyadic International, Inc. Announces Public Offering Pricing
Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a leading global biotechnology firm based in Jupiter, Florida, specializes in the scalable production of specialized proteins for various applications in life sciences, food, and industrial sectors. Recently, Dyadic revealed the pricing details of its underwritten public offering which involves 6,052,000 shares of common stock at an offering price of $0.95 per share. This strategic move is anticipated to generate gross proceeds of about $5.75 million, excluding underwriting discounts and associated offering expenses. The collective aim of this offering is to secure the necessary funds for working capital and overall corporate objectives.
Details of the Public Offering
The public offering's closure is projected for August 1, 2025, conditional on customary closing circumstances being met. Leading the offering is Craig-Hallum Capital Group LLC, positioned as the sole managing underwriter, leveraging their expertise to ensure the process proceeds efficiently.
Intended Use of Proceeds
Dyadic plans to deploy the net proceeds from this offering towards enhancing product development initiatives and bolstering sales and marketing strategies. This approach reflects the Company's commitment to innovation and its ongoing mission to deliver efficient, scalable, and sustainable biotech solutions to its partners across various markets.
Operating Under Effective Registration
The aforementioned securities are associated with an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3, which has facilitated this offering. Companies like Dyadic depend on such registrations to optimize capital-raising operations while remaining compliant with regulatory standards.
Overview of Dyadic Applied BioSolutions
Dyadic Applied BioSolutions harnesses proprietary microbial platforms to create recombinant proteins, strategically offered or licensed to partners within the life sciences, food and nutrition, and bio-industrial sectors. These high-quality proteins empower Dyadic's customers to design products that are more effective and sustainable, fulfilling evolving demands in biotechnology. Dyadic’s innovative C1 and Dapibus™ expression systems are crucial elements supporting cost-effective, flexible manufacturing processes vital for the success of commercial programs.
Commitment to Progress
As a company, Dyadic emphasizes continuous development and innovation in its commercial and partnered initiatives, underscoring the importance of harnessing biotechnology to foster growth in various industries globally. By utilizing state-of-the-art production methods, Dyadic is committed to enhancing the efficiency, scalability, and sustainability of the solutions it provides.
Frequently Asked Questions
What is the significance of Dyadic's public offering?
The public offering allows Dyadic to secure funding for critical operations, including product development and marketing strategies, which are essential for growth.
How many shares are being offered?
The Company is offering 6,052,000 shares of its common stock at a price of $0.95 each as part of this offering.
Who is managing the public offering?
Craig-Hallum Capital Group LLC is the sole managing underwriter for this offering, ensuring efficient handling of the process.
What will the proceeds be used for?
Dyadic intends to use the proceeds for working capital and general corporate purposes, targeting advancements in product development.
What is Dyadic’s core focus?
Dyadic is focused on the scalable production of high-value proteins for various sectors, utilizing proprietary gene expression platforms to enhance biotech innovation.
